Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14726 - 14750 of 14934 in total

Dipipanone

Experimental
Illicit

2,3,4,5,6-Pentafluorobenzyl Alcohol

Experimental

Balanol Analog 2

Experimental

N-[3-(aminomethyl)benzyl]acetamidine

Experimental

2-{4-[4-(4-Chloro-Phenoxy)-Benzenesulfonyl]-Tetrahydro-Pyran-4-Yl}-N-Hydroxy-Acetamide

Experimental

Diethyl 4-Methylbenzylphosphonate

Experimental

Iodobenzene

Experimental

1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea

Experimental

ES-936

Experimental

AL7182

Experimental

1-(N-Imidazolyl)-2-Hydroxy-2-(2,3-Dichlorophenyl)Octane

Experimental

(R)-Bicalutamide

Experimental

4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole

Experimental

4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid

Experimental

PAS219

Experimental

FR239087

Experimental

4-Fluorophenethyl Alcohol

Experimental

Phenacetin

Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn

4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid

Experimental

(P-Iodophenylacetylamino)Methylphosphinic Acid

Experimental

1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea

Experimental

N-(Chlorophenyl)-N'-hydroxyguanidine

Experimental

(R)-4-Nitrostyrene oxide

Experimental

Posizolid

Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational

Cannabinor

Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Investigational
Displaying drugs 14726 - 14750 of 14934 in total